Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
Other Sizes |
|
Targets |
Human Endogenous Metabolite
|
---|---|
ln Vitro |
Immune assays for cell surface E-selectin and secreted TNF-α showed that β-Damascenone also inhibits the upregulation of inflammatory proteins[1].
In vitro, when human cellular systems are activated by various inflammatory stimuli, β-Damascenone inhibits the NF-κB signaling pathway[1]. |
References |
Molecular Formula |
C13H18O
|
---|---|
Molecular Weight |
190.28142
|
Exact Mass |
190.135765193
|
CAS # |
23696-85-7
|
Related CAS # |
23696-85-7
|
Appearance |
Liquid
|
SMILES |
C/C=C/C(=O)C1=C(C=CCC1(C)C)C
|
InChi Key |
POIARNZEYGURDG-FNORWQNLSA-N
|
InChi Code |
InChI=1S/C13H18O/c1-5-7-11(14)12-10(2)8-6-9-13(12,3)4/h5-8H,9H2,1-4H3/b7-5+
|
Chemical Name |
(E)-1-(2,6,6-trimethylcyclohexa-1,3-dien-1-yl)but-2-en-1-one
|
Synonyms |
Damascenone; (E/Z)-Damascenone
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~525.5 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.2554 mL | 26.2771 mL | 52.5541 mL | |
5 mM | 1.0511 mL | 5.2554 mL | 10.5108 mL | |
10 mM | 0.5255 mL | 2.6277 mL | 5.2554 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Inhibition of IL-8 secretion in HUVECtert by β-damascenone (10). Front Pharmacol . 2019 Nov 28:10:1351. td> |
β-Damascenone at tested concentrations is not toxic. HUVECtert. Front Pharmacol . 2019 Nov 28:10:1351. td> |
β-Damascenone (10) inhibits TNF-α (2 ng/ml)-induced NF-κB-driven luciferase reporter gene transactivation concentration dependently; the inhibition is reversed in the presence of 5 mM glutathione (GSH). Front Pharmacol . 2019 Nov 28:10:1351. td> |